David earned a PhD in Biological Sciences from Columbia University in New York, NY, where he studied how Drosophila ovarian adult stem cells respond to cell signaling pathway manipulations. This work helped to redefine the organizational principles underlying adult stem cell growth models. He is currently a Science Writer, as part of the BioNews Services writing team.
The first patient has been dosed in Stoke Therapeutics‘ Phase 1/2a MONARCH trial, which is investigating the safety, tolerability, and efficacy of STK-001 as a treatment for children and adolescents ... Read more
Stoke Therapeutics has begun enrollment for its Phase 1/2a MONARCH study, investigating the safety, tolerability, and effectiveness of STK-001 in children and adolescents with Dravet syndrome. The MONARCH trial ... Read more
Note: This story was updated June 15, 2020, to note that Ashish Sagrolikar is Zogenix’s chief commercial officer, not its CEO. Pharmaceutical company Zogenix has launched “Shine Forward with ... Read more